AbbVie Inc. buy Piper Sandler
Start price
18.06.24
/
50%
€157.48
Target price
18.06.25
€176.97
Performance (%)
2.74%
End price
19.06.25
€161.80
Summary
This prediction ended on 19.06.25 with a price of €161.80. With a performance of 2.74%, the BUY prediction by Piper_Sandler for AbbVie Inc. closed with a slight gain. Piper_Sandler has a follow-up prediction for AbbVie Inc. where he still thinks AbbVie Inc. is a Buy. A total of €3.02 was paid as dividends for this prediction. Piper_Sandler has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| AbbVie Inc. | 3.760% | 3.760% | 0.409% |
| iShares Core DAX® | 0.648% | -0.148% | 32.392% |
| iShares Nasdaq 100 | -0.034% | 1.859% | 14.899% |
| iShares Nikkei 225® | 2.445% | 8.129% | 8.878% |
| iShares S&P 500 | 0.492% | 1.525% | 10.604% |
Comments by Piper_Sandler for this prediction
In the thread AbbVie Inc. diskutieren
AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Piper Sandler from $185.00 to $190.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat
In the thread Trading AbbVie Inc.
Die von Piper_Sandler gewählte maximale Laufzeit wurde überschritten